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Abstract: Prostate cancer is the most commonly diagnosed malignancy in men, claiming over 
350,000 lives worldwide annually. Current diagnosis relies on prostate-specific antigen (PSA) 
testing, but this misses some aggressive tumours, and leads to the overtreatment of non-harmful 
disease. Hence, there is an urgent unmet clinical need to identify new diagnostic and prognostic 
biomarkers. As prostate cancer is a heterogeneous and multifocal disease, it is likely that multiple 
biomarkers will be needed to guide clinical decisions. Fluid-based biomarkers would be ideal, and 
attention is now turning to minimally invasive liquid biopsies, which enable the analysis of 
tumour components in patient blood or urine. Effective diagnostics using liquid biopsies will 
require a multifaceted approach, and a recent high-profile review discussed combining multiple 
analytes, including changes to the tumour transcriptome, epigenome, proteome, and metabolome. 
However, the concentration on genomics-based paramaters for analysing liquid biopsies is 
potentially missing a goldmine. Glycans have shown huge promise as disease biomarkers, and 
data suggests that integrating biomarkers across multi-omic platforms (including changes to the 
glycome) can improve the stratification of patients with prostate cancer. A wide range of 
alterations to glycans have been observed in prostate cancer, including changes to PSA 
glycosylation, increased sialylation and core fucosylation, increased O-GlcNacylation, the 
emergence of cryptic and branched N-glyans, and changes to galectins and proteoglycans. In this 
review, we discuss the huge potential to exploit glycans as diagnostic and prognostic biomarkers 
for prostate cancer, and argue that the inclusion of glycans in a multi-analyte liquid biopsy test for 
prostate cancer will help maximise clinical utility. 
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1. Introduction 
Prostate cancer is the most common cancer in men, and is a major clinical burden [1]. In the 
last decade, research into prostate cancer has advanced rapidly, and large advances have been 
made in both finding new treatments and understanding the underlying biology. However, several 
areas of urgent unmet clinical need remain, including the identification of: (i) validated biomarkers 
to complement prostate-specific antigen (PSA) for screening; (ii) prognostic biomarkers with the 
clinical utility to distinguish indolent and aggressive disease; (iii) molecular stratification methods 
and predictive biomarkers; and (iv) surrogate end point biomarkers that are valid measures of 
therapeutic response and survival [2]. As prostate cancer is a heterogeneous and multifocal disease, 
it is likely that multiple biomarkers will be needed to guide clinical decisions. Fluid-based 
biomarkers would be ideal, and attention is now turning to minimally invasive liquid biopsies, 
which enable the analysis of tumour components in patient biological fluids such as blood and 
urine. Urine is an amenable bodily fluid for prostate cancer biomarker discovery. It is easily 
obtained in a non-invasive way, and due to the proximity of the prostate to the bladder, urine may 
carry markers that reflect the development and progression of prostate cancer [3]. Proximal fluids 
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of the prostate such as expressed prostatic secretions (fluid secreted by the prostate after a digital 
rectal prostate massage) can also be collected in urine and used as a source of biomarkers [4]. 
Whereas traditional tissue biopsies only provide limited snapshots of the tumour and might fail to 
reflect heterogeneity, liquid biopsies can provide a comprehensive view of all cancerous lesions 
(primary and metastases) as well as offering the opportunity to track tumour evolution [5]. 
A 2018 high-profile review in Nature Genetics highlighted that effective diagnostics using liquid 
biopsies will require the multiparametric analysis of several analytes (including changes to the 
transcriptome, epigenome, proteome, and the metabolome) within the same blood or urine sample 
[6]. The detection of changes to the glycome, and more specifically cancer-associated glycan sugar 
groups, was not included in this review. Glycans have shown huge promise as diagnostic 
biomarkers for cancer [7–9], and recent data suggests that integrating biomarkers across multi-omic 
platforms (which includes changes to the glycome) can improve the stratification of patients with 
prostate cancer [10].  
Glycans are saccharides that can be attached to proteins, lipids, and other glycans through the 
enzymatic process known as glycosylation. Glycosylation is the most common posttranslational 
modification, and is now known to be essential to virtually every biological process in the body 
[11]. Glycans can either be added sequentially to the hydroxyl oxygen of serine/threonine residues 
on the target protein (O-linked glycosylation), or as pre-assembled blocks of 14 sugars that are 
transferred co-translationally via the amide group of an asparagine residue on the target protein 
(N-linked glycosylation). How much a protein or lipid is glycosylated depends on the number of 
glycosylation sites present, and the expression of specific glycosylation enzymes within the cell [9]. 
Glycans are major building blocks of life [12], but have been hugely understudied (Figure 1). This is 
partly due to their complexity, the difficulties studying them, and that there is no clear link between 
glycans and DNA. However, this is now changing, and the importance of glycans can be 
conceptualised as an extended model of the central dogma (Figure 2). The technology to study 
glycans is rapidly advancing, and there is expected to be an explosion of interest in this area in the 
next 10 to 15 years, which will be helped by projects such as the human glycome project [13]. 
 
Figure 1. Glycans, the understudied major building blocks of life. The glycoproteome combines 
three highly adaptable interdependent biological alphabets. Created with BioRender. 
 
Figure 2. The importance of glycans can be conceptualised as an extended model of the central 
dogma. Created with BioRender. 
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Changes to glycans in cancer cells were first described 50 years ago [14], and confirmed by the 
development of antibodies against tumour-specific antigens [15]. Aberrant glycosylation is a 
universal feature of cancer cells, and cancer-associated glycans have been detected in virtually 
every cancer type [16,17]. Cancer cells have numerous changes to glycans compared to normal 
tissue, including changes to sialylation, fucosylation, the truncation of O-glycans, and N-glycan 
branching (see [18] for more details). The importance of glycans in cancer is emphasised by the 
majority of the Food and Drug Administration (FDA)-approved tumour markers being glycan 
antigens or glycoproteins [19–21]. Glycans have key roles in fundamental molecular and cell 
biology processes in cancer biology, including cell signalling, tumour cell invasion, immune 
modulation, angiogenesis, interactions with the cell matrix, and metastasis, which are linked to all 
of the recognised cancer hallmarks [17]. Glycans secreted by cancer cells likely represent the altered 
glycosylation status of cancer cells, and are a largely untapped resource of cancer biomarkers. There 
is a huge potential to exploit glycans to improve early diagnosis, as biomarkers for prognosis and 
stratification, and as markers of specific therapeutic targets [7].  
The physiological function of the prostate is to act as a secretory gland, which generates and 
secretes glycoproteins such as PSA into seminal fluid. As such, the prostate is a major secretor of 
glycans, and there is an unrealised opportunity to detect aberrant glycosylation patterns in serum 
and urine, and link this to prostate cancer status [22]. As prostate cancer progresses, the epithelial 
glands become smaller and more rounded, potentially having a drastic effect on the normal 
secretory pathways where proteins and lipids are glycosylated. Glycans can influence cell survival, 
proliferation, and metastasis, and likely play a key role in these processes in prostate cancer [22]. A 
wide range of alterations to glycans have been observed in prostate cancer, including changes to 
PSA glycosylation, increased sialylation and fucosylation, increased O-GlcNacylation, the 
emergence of cryptic and branched N-glyans, and changes to galectins and proteoglycans [22–24] 
(see tables 1–3 for more details). In this review, we discuss the huge potential to exploit glycans as 
diagnostic and prognostic biomarkers for prostate cancer, and argue that it will be essential to 
include glycans as part of a multi-analyte liquid biopsy test. 
2. PSA Glycosylation 
Prostate-specific antigen (PSA) is a glycoprotein enzyme that has been used widely as a 
biomarker for prostate cancer, but has the disadvantage of low specificity and no prognostic value 
at diagnosis [25]. PSA screening for prostate cancer has led to the overdiagnosis and overtreatment 
of indolent disease, resulting in unnecessary biopsies and treatments for non-aggressive cancers 
[26,27]. Refinements on the PSA test, such as the Prostate Health Index (PHI) and 4Kscore, can 
improve diagnostic accuracy, but have limited prognostic utility, and may miss some high-grade 
cancers [28]. Thus, there is an urgent clinical need to shift the focus to identifying aggressive disease 
that needs immediate treatment [29–31]. Advances in mass spectrometry have led to an increased 
interest in glycan structures on cancer-associated proteins, and numerous studies have investigated 
whether a glycan signature on PSA can be used to improve its clinical utility [21,24]. A recent study 
also linked a single nucleotide polymorphism that affects PSA glycosylation to prostate cancer risk 
[32]. PSA has a single N-glycosylation site at asparagine-69 (Asn-69) [24]. Approximately 50 
glycoforms of PSA have been described, but only some of these are found in aggressive prostate 
cancer. In particular, complex biantennary glycoforms with α2,3-sialic acid have been closely linked 
to aggressive disease in multiple studies [33–35] (Table 1). When combined with the PHI, the 
detection of α2,3-sialic acid PSA glycoforms in a cohort of 79 patients showed 100% sensitivity and 
94.7% specificity to differentiate high-risk prostate cancer from low-risk and benign disease [34]. 
The robust prediction power of α2,3-sialylated PSA to diagnose aggressive prostate cancer has been 
confirmed by other studies using independent cohorts and different technologies [35]. Together, 
these studies provide strong evidence in support of the clinical utility of PSA glycoforms to 
distinguish indolent and aggressive prostate cancer. 
3. Sialyled Glycans 
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Sialylation is the process by which sialic acid residues are added to glycans as the terminal 
monosaccharide. Abnormal sialylation is a universal feature of cancer cells that is linked to poor 
prognosis and metastasis [9,36–40]. In prostate cancer, sialic acid levels have been investigated as an 
adjunct to PSA in predicting prostate malignancy [41,42]. Increased levels of α2-3-linked sialic acid 
have been detected on serum glycoproteins in patients with prostate cancer compared to benign 
prostatic hyperplasia (BPH), and can be used to predict Gleason score with a higher specificity and 
sensitivity than PSA [43,44]. Serum sialic acid levels have also been linked to pathological grade, 
and elevated sialic acid may predict bone metastasis [45]. Together, these studies suggest serum 
sialic acid as a promising diagnostic biomarker for prostate cancer that should be further 
investigated for use in predicting disease progression. 
An emerging tool for glycoproteomic analysis is the use of azide sugar analogs as mimics of 
sialic acid. This strategy utilises metabolically labelled glycans with chemical reporters that are 
ligated to fluorescent probes, and offers a new avenue for probing changes to the glycome by both 
imaging and glycoproteomic analyses [24,46]. In prostate cancer, sialic acid analogs have been used 
to identify sialoglycoproteins linked to metastatic potential in cell lines derived from PC3 cells [47]. 
More recently, sugar azide analogs have been utilised in prostate cancer tissue slices to identify 
glycoproteins that are elevated or uniquely found in prostate cancer cells [48].  
As well as changes to serum sialic acid levels and sialoglycoproteins, tumour-associated 
sialylated glycans also change in prostate cancer. Numerous studies have reported the upregulation 
of the sialylated blood group antigen Sialyl Lewis X (SLeX) in prostate cancer, and linked this with 
poor prognosis in patients [49–52] (Table 1). SLeX, and its isomer SLeA, are the minimal recognition 
motif for ligands of selectins, which is a family of lectins with roles in leukocyte trafficking and 
tumour extravasation [53]. SLeX could influence prostate cancer progression through numerous 
mechanisms, including binding to E-selectin, the evasion of Natural Killer (NK) cell immunity, and 
the promotion of bone metastasis [52,54–56]. The upregulation of SLeX has been detected on PSA, 
Mucin 1 (MUC1), and prostatic acid phosphatase (PAP) proteins in a panel of 10 malignant tissues 
(relative to matched normal tissue), opening up a new avenue for the development of prostate 
cancer-specific glycoprotein biomarkers [57]. The cancer-associated sialyl-Tn glycan (known as sTn) 
has also been linked to prostate cancer. sTn is a truncated O-glycan containing a sialic acid α-2,6 
linked to GalNAc α-O-Serine/Threonine (Ser/Thr) (Table 1). The sTn glycan is upregulated in 
several cancer types and associated with metastasis and poor prognosis [37]. In prostate cancer, sTn 
is expressed in high-grade prostate tumours [58,59], and can reduce prostate cancer cell adhesion 
[60,61]. The sTn antigen is being widely investigated as a circulating biomarker for other cancers 
[62,63], and it is likely that innovative tools that were developed to detect sTn [63–65] will also have 
clinical utility for prostate cancer precision oncology.  
Table 1. Summary of glycan alterations in prostate cancer. PSA: prostate-specific antigen. 
Glycan 
Structure Link to Prostate Cancer References 
Example of N-
glycan on PSA 
α2-3 sialylated N-glycan 
Complex biantennary glycoforms with α2,3-sialic 
acid have been closely linked to aggressive disease in 
multiple studies.  
[33–35]. 
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Sialyl Lewis X 
(SLeX) 
 Upregulated and linked to poor prognosis in 
patients. Detected on PSA, MUC1 and PAP in 
malignant tissue 
[49–52,57]. 
Sialyl Tn (sTn)  Expressed in high-grade prostate tumours. Can 
reduce prostate cancer cell adhesion. 
[58–61] 
Core Fucosylation  Increased in patient serum. Linked to aggressive 
disease. 
[43,66–68] 
Levels correlate with Fucosyltransferase 8 (FUT8). [69] 
O-GlcNAcylation  Upregulated and linked to poor prognosis in 
primary prostate cancer. 
[70,71] 
Downregulated in castrate resistant prostate 
cancer(CRPC). 
[72] 
Branched N-
glycans 
 
Linked to metastasis and disease-free survival. [73] 
Predictive biomarker for CRPC. [74] 
R 
α3 
β4 
β2 
α3 
β4 
β2 
α3 α6 
β4 
α6 
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Cryptic N-glycans  N-linked oligomannose 9 (Man9) is increased in 
high-grade tumours and linked to clinical outcome. 
[75] 
 
4. Fucosylation 
Fucosylation describes the attachment of a fucose residue to a glycan, and consists of terminal 
fucosylation and core fucosylation. Increased core fucosylation has been detected in the serum of 
patients with prostate cancer, is associated with disease progression [43,67,68] (Table 1), and may 
influence prostate cancer cell trafficking through an E-selectin dependent mechanism [56]. The 
fucosyltransferase FUT8 is the only enzyme responsible for the α-1,6-linked core fucosylation that 
adds fucose to the inner GlcNAc on N-glycans [76]. FUT8 expression is increased in high-grade and 
metastatic prostate cancer [73,77]. The increased fucosylation of glycoproteins in aggressive 
prostate cancer correlates with FUT8 [69], and this has been recently linked to castrate resistance, 
cell survival, and lower PSA production [78] (Table 1). Taken together, these findings implicate 
dysregulated fucosylation in prostate cancer progression and the development of castrate 
resistance. In line with this, several fucosylated glycoproteins are being investigated as potential 
non-invasive predictive biomarkers. These include decreased fucosylation on PSA [33,79] and 
integrins [80], and elevated fucosylated haptoglobin [68]. 
5. O-GlcNAcylation 
The addition of O-GlcNAc to proteins (known as O-GlcNAcylation) plays a fundamental role 
in cellular processes, including transcription, epigenetics, cell signalling, proteostasis, and 
bioenergetics [81,82] (Table 1). In cancer cells, elevated pools of Uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc) drive the O-GlcNAcylation of key targets in the cytoplasm, 
nucleus, and mitochondrion, and can alter key hallmarks of cancer [83,84]. O-GlcNAcylation is 
catalysed by O-GlcNAc transferase (OGT) (for more details, see [85]). OGT uses UDP-GlcNAc as a 
substrate, which is produced by the hexosamine biosynthetic pathway (HBP). HBP acts as a sensor 
for the nutritional state of the cell, and has a key role in the metabolic rewiring observed in cancer 
[86]. In primary prostate cancer, global O-GlcNAcylation is elevated relative to benign disease [70], 
and O-GlcNAc levels correlate with a higher Gleason score and reduced patient prognosis [71]. 
Both OGT and enzymes in the HBP pathway change in prostate cancer. OGT is upregulated in 
primary prostate cancer, and this is linked to a higher Gleason score, reduced time to biochemical 
recurrence, and increased c-Myc stability [87]. Similarly, UDP-N-Acetylglucosamine 
Pyrophosphorylase 1 (UAP1,the last enzyme in the HBP) is also overexpressed in prostate cancer 
tissue [88]. Although HBP is upregulated in localised prostate cancer where it promotes disease 
progression, in advanced castrate-resistant disease, the inhibition of HBP enhances tumour growth 
[72]. Metabolic rewiring during disease progression is believed to promote the downregulation of 
HBP in castrate-resistant disease, and in particular, loss of the Glucosamine-Phosphate N-
Acetyltransferase 1 (GNPNAT1) enzyme may serve as a marker of progression to castrate resistance 
[72]. 
Man5 
Man9 
R 
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6. Branched and Cryptic N-Glycans  
Changes to N-glycans are common in cancer, and have been linked to metastasis in multiple 
tumour types [89,90]. Common changes include the branching of complex biantennary glycans to 
triantennary and tetraantennary structures, and the emergence of cryptic N-glycans [9] (Table 1). In 
prostate cancer, β-1,6-GlcNAc tri-branched and tetra-branched N-glycans are linked to both 
metastasis in xenograft models and disease-free survival in patients [73]. Serum N-glycan 
signatures have shown promise as diagnostic and predictive biomarkers in prostate cancer [91]. 
Changes to branched N-glycans can help distinguish BPH and prostate cancer [43,92], and 
increased serum triantennary and tetraantennary N-glycans have clinical utility to predict castrate-
resistant prostate cancer [74]. In recent work, a muti-omic study identified tetraantennary and 
tetrasialylated N-glycans using mass specrometery as part of a biomarker panel to improve the 
stratification of patients with indolent and aggressive prostate cancer, and predict patient survival 
[10]. 
Cryptic N-glycans are the precursors, cores, and internal sequences of N-glycans that are 
usually masked by other sugar moieties, but occur in cancer due to alterations in glycan synthesis 
and processing [22,93]. As illustrated in Table 1, they contain the same mannose cores, but differ in 
the terminal sugar moieties. Cryptic N-glycans expose internal sequences that are normally ‘cryptic’ 
to the immune system [94]. Several studies have investigated how cryptic N-glycans change among 
different Gleason grades of prostate cancer and in metastatic disease [73,94–96]. Of particular 
interest, the cryptic N-glycan Man9 has been detected in the serum of men with prostate cancer, 
and serum Man9 autoantibodies may help differentiate high-grade tumours and predict clinical 
outcome [75]. The further development and validation of assays to detect anti-Man9 antibodies in 
patient serum is expected to be useful clinically. 
7. The F77 Antigen 
An antibody against the F77 antigen was initially isolated from mice injected with PC3 cells, 
and has provoked great interest as a prostate cancer-specific diagnostic and therapeutic tool. F77 
was first identified as a glycolipid with α1,2-fucose linkages, and linked to the glycosylation 
enzymes Fucosyltransferase 1 (FUT1) and Core 2 Branching Enzymes 1-3 (GCNT1, GCNT2, and 
GCNT3) [97–99]. However, F77 has since been detected on O-glycan proteins, including a spliced 
isoform of CD44 found in the sera of prostate cancer patients [100]. The antibody against F77 can 
inhibit the growth of PC3 and DU145 tumour xenografts in nude mice, and can be used to 
differentiate primary and metastatic prostate cancer from non-malignant prostate tissue, [99]. 
Immunohistochemistry staining tissue sections detected F77 in 112 of 116 primary and 29 of 34 
metastatic prostate cancer tissues, while no signal was detected in normal prostate tissue [99]. 
8. Glycolipids 
Many of the glycans found attached to proteins are also found on glycolipids (glycolipids are 
lipids modified by one or more glycans). The aberrant expression of glycolipids in cancer has 
potential roles in disease progression and anti-tumour immunity (see [101] for more details). In 
prostate cancer, the F77 antigen (see Section 7 above) is known to contain a glycolipid with α1,2-
fucose linkages, and preliminary studies have linked increased ganglioside GD1a to castrate-
resistant disease [102,103].  
9. Proteoglycans  
Proteoglycans are proteins that are heavily glycosylated. The core protein has one or more 
glycosaminoglycan (GAG) chains attached (such as chondroitin sulphate, heparin sulphate, or 
keratin sulphate). Proteoglycans are a major component of the extracellular matrix and interact with 
growth factors, chemokines, and other extracellular matrix proteins. They have roles in cell 
signalling, adhesion, cell growth, and apoptosis, and have an established role in cancer progression 
[104]. Several proteoglycans have been found to be important in prostate cancer, including versican, 
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decorin, biglycan, lumican, and syndecan-1 (summarised in Table 2), and data from a range of 
studies implicate proteoglycan alterations to prostate cancer cell survival and metastasis [105]. 
Proteoglycan expression patterns might be useful as predictive and prognostic biomarkers in 
patients with prostate tumours [22]. Of particular interest, increased levels of versican [106], 
biglycan [107], and syndecan-1 [108,109] are linked to poor prognosis. 
Table 2. Proteoglycans with roles in prostate cancer. 
Proteoglycan Link to Prostate Cancer References 
Versican 
Modulates binding to the extracellular matrix (ECM) and enhances motility.  
Associated with poor prognosis. 
[106,110–112] 
Decorin 
Suppresses tumour growth by inhibiting both androgen receptor (AR) and epidermal 
growth factor (EGF). Decreased in prostate cancer. 
[106,113,114] 
Biglycan Associated with poor prognosis and PTEN deletion. [107] 
Lumican 
Lumican in stroma tissue suppresses cancer progression. Potential marker in prostate 
cancer staging. 
[115] 
Perlecan Linked to disease progression. Upregulates sonic hedgehog signalling. [116,117] 
Syndecan-1 
Role in the epithelial-to-mesenchymal transition (EMT). Maintains stability of prostate 
tumour initiating cells. 
[118,119] 
Poor prognosis. [108,109] 
10. Galectins 
Cancer cells may also display altered expression of proteins that interact with glycans. A key 
example of this is the galectins, which are a group of glycan-binding proteins with an established 
role in tumour biology [120]. Several galectins have been implicated in prostate cancer biology 
(summarised in Table 3). A unique galectin signature has been identified in prostate cancer tissue, 
with the upregulation of galectin-1 and downregulation of galectins 3, 4, 9, and 12 observed during 
disease progression [121]. Of particular interest, galectin-3 is linked to tumour progression [122] 
and has a role in the prostate cancer bone metastasis niche [123]. Immunohistochemistry staining of 
galectin-3 in tissues from 83 patients had 91.7% sensitivity, 64% specificity, and 73% accuracy in 
predicting PSA biochemical recurrence [124]. 
Table 3. Galectins with roles in prostate cancer. 
Galectin Link to Prostate Cancer References 
Galectin-1 
Upregulated during disease progression. Linked to angiogenesis.  [121] 
Potential therapeutic target in CRPC. [125,126] 
Galectin-3 
Promotes prostate tumour growth and invasion. Potential diagnostic marker. [127] 
High in early stages, lost in advanced disease. May predict biochemical recurrence. [123,124] 
Role in bone metastasis niche. [122] 
Galectin-4 
Linked to metastasis and reduced survival. [128] 
Part of O-glycosylation-mediated signalling circuit drives metastatic CRPC. [129] 
Galectin-8 Linked to metastasis. Proposed as prognostic biomarker. [130] 
11. Upregulation of Glycosylation Enzymes 
One of the underlying causes of aberrant glycosylation in cancer is the dysregulated expression 
of glycosylation enzymes within the cancer cell [16]. Growing evidence links the differential 
expression of glycosylation enzymes to the progression of prostate cancer [57,78,88,131–136] 
(summarised in Table 4). Androgens are known to drive the development and progression of 
prostate cancer, and the first line of treatment for men with advanced disease is androgen 
deprivation therapy (ADT) [137]. Recently, we identified a set of glycosylation enzymes that were 
regulated by androgens both in seven men undergoing ADT, and in prostate cancer cell lines. 
Importantly, these enzymes are linked to prostate cancer cell survival, and are upregulated in 
primary prostate cancer relative to normal and benign tissue [131,132]. The androgen-regulated 
glycosylation enzymes in prostate cancer include: (i) ST6GalNac1, which synthesises the cancer-
associated sTn antigen, (ii) GCNT1, which is linked to the synthesis of sLeX, (iii) GalNAc transferase 
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7 (GALNT7), which is part of a gene signature associated with androgen receptor splice variant-7 
(AR-V7), and (iv) the HBP enzyme UAP1, which is highly overexpressed in prostate cancer 
[57,60,88,132,138]. Several cancer-associated glycans, including sTn, Tn, and sLeX are also androgen 
regulated in prostate cancer cell lines [132], but this is yet to be studied in primary patient tissue. 
Preliminary studies have found that GCNT1 can be detected in post-digital rectal examination 
(post-DRE) urine from 35 prostate cancer patients by immunoblotting, and used to predict the 
extracapsular extension of prostate cancer (the receiver operating characteristic (ROC) curve 
analysis for GCNT1 was 0.7614, compared to 0.7455 for PSA) [139]. The UAP1 gene can also be 
detected in plasma and urine, and can be used as part of a gene panel to predict prostate biopsy 
results and prognosis [140,141]. Altered expression of the fucosyltransferases FUT6 and FUT8 are 
important in advanced prostate cancer. FUT6 is upregulated in distant metastases, and may play a 
role in metastasis to bone [136]. FUT8 expression increases in aggressive and castrate-resistant 
prostate cancer, and is linked to poor prognosis in patients (these studies were based on cell lines, 
and a small number of tissue samples and will need repeating in additional larger cohorts) [77,78]. 
Taken together, these studies suggest that glycosylation enzymes are a promising but yet 
unexploited resource of diagnostic and prognostic biomarkers for prostate cancer, and may also 
provide new insights into candidate glycoprotein alterations. 
Table 4. Summary of glycosylation enzymes with roles in prostate cancer. HBP: hexosamine 
biosynthetic pathway. 
Glycosylation 
Enzyme 
Role in Glycosylation Link to Prostate Cancer References 
ST6GALNAC1 
Transfers α-2,6 sialic acid 
to O-linked GalNAc 
Regulated by androgens. Upregulated in tumour tissue. Linked 
to the synthesis of sTn. Reduced cell adhesion 
[60,61,142] 
GCNT1 
Forms core-2-branched O-
linked glycans 
Increased in aggressive disease. Closely related to 
extraprostatic extension and lymph node metastasis. Increases 
tumour growth on orthotopic inoculation into the mouse 
prostate. 
[133,134] 
Resistance to NK cell immunity. [52] 
Regulated by androgens [132] 
Associated with higher levels of core 2 O sLex in PSA, PAP, 
and MUC1 
[57] 
Linked to F77 antigen. [97] 
Detected in post-DRE urine. Indicator of extracapsular 
extension 
[139] 
GCNT2 
Forms core-2-branched O-
linked glycans 
Linked to invasion. Potential role in integrin signalling. [143] 
GALNT7 
Initiation of O-
glycosylation 
Upregulated in malignant PCa as part of a glycosylation gene 
signature. 
[144] 
Androgen regulated and linked to prostate cancer cell viability. [132] 
Correlates with AR-V7 in CRPC. [138] 
C1GALT1 
Generates the common 
core 1 O-glycan structure 
Part of O-glycosylation mediated signalling circuit that drives 
CRPC and is linked to poor survival. 
[129] 
ST6Gal1 
Addition of sialic acid to 
galactose-containing N-
glycan 
Upregulated. Linked to reduced survival and metastasis. [135] 
Regulated by androgens. [132] 
EDEM3 
Mannose trimming of N-
glycans 
Upregulated in malignant prostate cancer as part of a 
glycosylation gene signature. 
[144] 
Androgen regulated and linked to prostate cancer cell viability. [132] 
MGAT5 
Biosynthesis of β1,6 
GlcNAc-branched N-
glycans 
Link to metastasis in mouse models. [145] 
UAP1 
Last enzyme in HBP 
pathway. Produces  UDP-
GlcNAc 
Highly overexpressed (correlates negatively with Gleason 
score). Linked to increased UDP-GlcNAc. Protects prostate 
cancer cells from endoplasmic reticulum (ER) stress.  
Regulated by androgens. 
[88] 
GNPNAT1 
HBP pathway. Produces 
UDP-GlcNAc 
GNPNAT1 is decreased in CRPC. [72] 
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FUT6 Fucosylation 
Upregulated in distant metastases. Role in prostate cancer 
metastasis to bone. 
[136] 
FUT8 
Transfers fucose to core-
GlcNAc of the N-glycans 
Increased in aggressive prostate cancer and linked to poor 
prognosis. 
[77] 
Increased in CRPC. [78] 
12. Exosomes 
Exosomes are small vesicles secreted from most cell types that are present in body fluids. There 
is increasing evidence that exosomes are involved in carcinogenesis, and they are emerging as a rich 
source of tumour-specific proteins and biomarkers for cancer detection and progression [146]. 
Exosomes secreted by the prostate are structurally unique, and can be isolated from seminal fluid, 
tissue, blood, or urine for further analyses, providing a novel and easily isolatable source of 
tumour-specific proteins [147]. Glycans are important in exosome function [148]. A recent review 
discussed the potential to exploitexosomes as powerful tools to diagnose aggressive prostate cancer 
as early as possible, as well as predict patient prognosis and response to treatment [149]. Exosomes 
are a rich source of glycans [23,150], but are still largely unexplored in prostate cancer. The profiling 
of N-linked glycans from prostate cancer exosomes indicates a global decrease in large branched 
triantennary and tetraantennary glycans that reflects clinical status [151]. A better understanding of 
the presence of glycoproteins and glycan profiles of exosomes could improve current approaches of 
diagnosis and prognosis. As discussed by Tkac et al., glycan markers are likely to be enriched in 
exosomes, which will aid in assay design [23]. 
13. Tissue Imaging of Glycans 
Changes to glycans can be profiled in clinically relevant tissues using recently developed 
innovative approaches. A sialyltransferase-based chemoenzymatic histology assay can detect 
differences between unsialylated glycans in normal, cancerous, and metastatic prostate tissue 
sections [152], and bioorthoganol labelling has been used to identify sialoglycoproteins in prostate 
cancer tissue slices [48]. Advances in imaging mass spectrometry mean that glycans can now be 
identified directly on patient tissue, allowing for analysis of the spatial distribution of glycans. N-
glycans can be profiled on formalin-fixed paraffin embedded (FFPE) tissue samples and tissue 
microarrays (TMAs) using matrix-assisted laser desorption/ionization imaging mass spectrometry 
(MALDI-IMS) [24,153–155]. In this recently developed approach, glycans are released from their 
protein carrier and analysed directly on tissue. More than 40 individual glycan structures can be 
detected, and tumour-specific glycans can be grouped relative to histopathology localisations [155]. 
A major advantage of MALDI-MS imaging is that the best starting material is FFPE tissue, which is 
widely available in pathology labs. Ongoing work in this emerging area aims to identify tumour-
specific glycan biomarker panels indicative of aggressive prostate cancer, as well as identify a 
second tier of biomarkers by linking glycans back to their original glycoprotein carriers [23]. It is 
hoped that information on the various types of glycans within cancer tissue can be used in the 
future to enable the development of lectin-based assays for use in the pathology lab [155]. 
14. A Multi-Omic Liquid Biopsy Test 
The development and progression of prostate cancer from localised, organ-confined disease to 
biochemically progressive and then to metastasis is prolonged. To capture this evolving landscape, 
serial tissue biopsies are needed, which is difficult and costly to execute in the clinic. In addition, 
prostate cancer preferentially metastasises to bone, which is a site that is very difficult to sample. 
Tumour heterogeneity can also lead to aggressive tumours being missed, or underestimation of the 
tumour landscape [156]. Liquid biopsies offer a potential solution to overcome the practical and 
technical challenges of the traditional tissue biopsy [157]. The concept of a ‘liquid biopsy’ relies on 
the principle that cancer cells are shed directly into blood, urine, and other body fluids. These 
cancer cells can be captured and used to derive information to improve diagnosis, prognosis, or 
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treatment. Liquid biopsies may also capture a more complete representation of a cancer, which 
encompasses tumour heterogeneity [158]. 
Flow cytometery techniques were able to detect circulating prostate cancer cells in men with 
metastatic disease as early as the 1970s [159]. Today, technologies can use bodily fluids to profile 
genomic mutations, copy number alterations, and obtain information about the tumour 
transcriptome, epigenome, proteome, metabalome, and glycome. Among prostate cancer liquid 
biopsies, circulating tumours cells (CTCs) are the most extensively evaluated biomarkers [160], but 
other clinically relevant phenotypes have also shown promise. These include detection of the 
androgen receptor variant V7 (AR-V7) [161], circulating miRNAs [162–164], TMPRSS2:ERG, and 
prostate cancer antigen 3 (PCA3) [165–167], circulating free DNA (cfDNA) (reviewed in [158]), 
detection of gene methylation [168,169], and the analysis of tumour-derived exosomes [170]. 
Individual biomarkers in liquid biopsy can often not accurately predict disease state due to 
heterogeneity in phenotype across individuals and over time. To address this challenge, effective 
diagnostics using liquid biopsies will require multiparameter strategies to combine information 
from multiple analytes. A recent study by Murphy et al. suggested that integrating biomarkers 
across multi-omic platforms (including changes to the epigenome, transcriptome, proteome, and 
glycome) can improve the stratification of patients with prostate cancer [10]. By the analysis of four 
types of DNA methylation, four coding and nine non-coding RNAs, 27 peptides, and 13 glycans (in 
a cohort of 158 radical prostatectomy patients), combined with clinical parameters, it was possible 
to effectively distinguish indolent and aggressive prostate cancer with area under the ROC curve 
(AUC) = 0.91 (age, PSA level, Gleason score, and DRE gave an AUC of 0.67). This strongly suggests 
that multivariate models (built from different -omics data) will lead to superior accuracy over 
individual markers for prostate cancer diagnosis and disease stratification [10], and together with 
the data discussed in this review, clearly demonstrate that the inclusion of glycans in a multi-
analyte liquid biopsy test for prostate cancer should help improve clinical utility.  
15. Conclusions and Future Perspectives 
Glycans contribute to many aspects of prostate cancer, and likely represent a huge and largely 
untapped resource of biomarkers with clinical utility. The summary provided by this review 
suggests that glycan-based biomarkers should be exploited as powerful tools to diagnose prostate 
cancer as soon as possible, and to accurately determine tumour aggressiveness and patient 
prognosis. Liquid biopsies hold great potential as non-invasive assays to monitor tumour 
heterogeneity and evolution, and select personalised therapy. As new markers are identified, their 
clinical impact must be translated through assay development, followed by clinical reproducibility 
and sensitivity testing [171]. These efforts raise new biological and technical challenges [158,172], 
yet constitute critical steps towards precision oncology. The ultimate goal in the field will be to 
clinically validate several types of molecules, including glycans, within a multi-analyte liquid 
biopsy test. Furthermore, looking towards the future, artificial intelligence-based tools may be 
useful to automatically discover and detect these signatures and move the field towards 
multiparametric analyses [173]. Alongside this, the development of novel glycan-targeting drugs 
(for examples, see [174–179]) will likely lead to new personalised glycan-based therapies. 
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